Study identifier:NIS-GBE-NEX-2006/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An epidemiological, observational study to describe symptom control and impact on daily life of GERD in patients with erosive gastroesophageal reflux disease.
GERD
-
No
-
All
2001
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2012 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The aim of this study is to gather epidemiological data in a population of GERD patients in primary care with a history of erosive esophagitis (less than or equal to 3 years).
Location
Location
Bruxelles, Belgium
Location
Rixensart, Belgium
Location
Jodoigne, Belgium
Location
Lasne, Belgium
Location
Court-Saint-Etienne, Belgium
Location
Hoeilaart, Belgium
Location
Tollembeek, Belgium
Location
Dilbeek, Belgium
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.